RxDoctor Payments Data

Adam Wanner, MD

Pulmonary Disease · Miami, FLNPI 1013925684

Payments from drug & device makers

$193,480in general payments, 2019–2025

Across 34 payments — averaging $5690.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$155K
  • Mallinckrodt Hospital Products Inc.$19K
  • GSK$6K
  • Merck$6K
  • Astrazeneca AB$4K
  • Astrazeneca UK Limited$4K
  • plus $31 from 1 others

What the payments were for

  • Consulting fees$18,97293%
  • Travel & lodging$1,2206%
  • Food & beverage$2761%
  • Education$150%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,480 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$23,635
Medicare patients
126
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,501
Spiriva HandihalerTiotropium Bromide44$23,426
Combivent RespimatIpratropium/Albuterol Sulfate13$15,842
Breo ElliptaFluticasone/Vilanterol24$10,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,694
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$8,700
SymbicortBudesonide/Formoterol Fumarate24$5,995
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,291
Tiotropium Bromide11$4,564
Advair HfaFluticasone Propion/Salmeterol12$4,520
Wixela InhubFluticasone Propion/Salmeterol49$4,051
Advair DiskusFluticasone Propion/Salmeterol15$3,943
Albuterol Sulfate HfaAlbuterol Sulfate134$3,029
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,447
Ventolin HfaAlbuterol Sulfate33$2,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$5,838$39,36165 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$154,884$24,38956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →